Insider Trading Alert - MDVN, ACOR, MDT, UHS And CTSH Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 4, 2013, 189 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $160.56 to $35,901,027,172.20.

Highlighted Stocks Traded by Insiders:

Medivation (MDVN) - FREE Research Report

Hung David who is President and CEO at Medivation sold 15,050 shares at $62.61 on Dec. 4, 2013. Following this transaction, the President and CEO owned 950,204 shares meaning that the stake was reduced by 1.56% with the 15,050-share transaction.

Machado Clarence Patrick who is Chief Business Officer and CFO at Medivation sold 5,425 shares at $62.66 on Dec. 4, 2013. Following this transaction, the Chief Business Officer and CFO owned 30,830 shares meaning that the stake was reduced by 14.96% with the 5,425-share transaction.

The shares most recently traded at $61.70, down $0.96, or 1.55% since the insider transaction. Historical insider transactions for Medivation go as follows:

  • 24-Week # shares sold: 30,885

The average volume for Medivation has been 1.3 million shares per day over the past 30 days. Medivation has a market cap of $4.7 billion and is part of the health care sector and drugs industry. Shares are up 22.4% year-to-date as of the close of trading on Wednesday.

Medivation, Inc., a biopharmaceutical company, focuses on development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. Currently there are 10 analysts that rate Medivation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDVN - FREE

TheStreet Quant Ratings rates Medivation as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and generally high debt management risk. Get the full Medivation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Medivation Founder Takes Helm at Axovant, Shares Spike

Second-Quarter Picks and Pans

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors